Lv4
460 积分 2024-10-12 加入
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumors
1天前
待确认
Chapter 13.0. FFR, iFR, CFR, and IMR: Results from clinical trials
21天前
已完结
FFRCT: Decision-maker or innocent bystander?
22天前
已完结
Abstract 1628: A small-molecule inhibitor of WRN selectively kills MSI-H cancer cells and phenocopies WRN genetic defects
26天前
已关闭
Research Progress in DNA Damage Response (DDR)-Targeting Modulators: from Hits to Clinical Candidates
26天前
已完结
Roles of RecQ Family Helicases in the Maintenance of Genome Stability
27天前
已关闭
Structural mechanisms of human RecQ helicases WRN and BLM
27天前
已完结
Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers
27天前
已完结
Microsatellite instability and DNA mismatch repair deficiency detection in tumors of various sites
28天前
已关闭
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
28天前
已完结
皖公网安备34019202002308
